Abstract Results
Study Design

Limitations
To address inherent limitations of epidemiologic observational studies, we employed propensity score-matching to correct for sample selection bias due to observable differences between the treatment and comparison groups. 
Statistics
Univariate analysis cross cohort comparison of patient demographics, severity, comorbidities, and type of providers. Differences between cohorts were analyzed using Chi-square for categorical variables and Wilcoxon rank-sum tests for continuous variables.
Patients were matched using propensity scoring for age, gender, Charlson co-morbidity index, and pre-index total costs.
Generalized linear models, adjusted for potential confounders (gender, age, severity, plan type, payer type, geographical region, physician specialty, pre-index co-morbidities, and pre-index total health care costs) were used to assess differences in health outcomes.
Index Date:
The date associated with the first claim for meeting the criteria for diagnosis of SHPT or SHPT proxy. CKD Diagnosis: During the pre-index period CKD was identified based on at least 1 medical or facility claim. SHPT or SHPT Proxy:
•At least 1 medical or facility claim of SHPT.
•At least 1 medical or facility claim of hyperphosphatemia.
•At least 2 pharmacy claims of phosphate binder treatment.
•At least 2 pharmacy claims of treatment with VDR activator. Cohort 1: Received paricalcitol. Cohort 2: Did not receive paricalcitol, calcitriol, doxercalciferol or cinacalcet prior to index. Follow-up: Length of follow-up varies beyond a minimum 3 months after index date, and terminates as of the date of dialysis, death or health plan disenrollment, which ever comes first. Cohorts were matched using propensity scoring of age, gender, Charlson Co-morbidity Index, and preindex total cost. 
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